Acorda Competitors

Delisted . USA . 
Stock . Acorda Therapeutics
ACORDelisted Stock  USD 16.20  0.40  2.41%   
Acorda Therapeutics competes with Shionogi, Pacira BioSciences,, Sunshine Biopharma, Biofrontera, and Shuttle Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Acorda Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Acorda Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Acorda Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
16.2016.2016.20
Details
Intrinsic
Valuation
LowRealHigh
12.6012.6017.82
Details

Acorda Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Acorda Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Acorda and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Acorda Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
LFCR
+ 0.73
PCRX
JUPW
+ 0.71
TAIPY
LFCR
+ 0.57
SBFMW
BFRI
+ 0.53
TAIPY
JUPW
+ 0.5
BFRI
SBFMW
+ 0.49
PCRX
  
High negative correlations   
LFCR
- 0.66
SHPH
SHPH
- 0.64
SBFMW
SHPH
- 0.62
PCRX
LFCR
- 0.55
SGIOF
PCRX
- 0.52
SGIOF
LFCR
- 0.46
OASMY

Risk-Adjusted Indicators

There is a big difference between Acorda Stock performing well and Acorda Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Acorda Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TAIPY  0.66  0.01 (0.02)(0.09) 1.40 
(7.27)
 0.00 
(0.78)
 16.67 
SGIOF  12.35  4.06  0.10  24.94  12.25 
(84.96)
 6.53 
(7.59)
 272.95 
OASMY  5.71 (0.21) 0.00  0.02  0.00 
 0.00 
 0.00 
(16.67)
 190.00 
PCRX  2.05  0.56  0.20 (1.39) 1.82 
(2.46)
 4.58 
(3.21)
 17.06 
SBFMW  17.95  4.17  0.19 (0.81) 15.52 
(24.81)
 52.17 
(28.00)
 110.63 
LSDI  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
BFRI  6.40 (0.05)(0.01) 0.00  7.29 
(8.02)
 14.63 
(11.70)
 46.72 
JUPW  4.58  0.42  0.06  4.79  4.91 
(6.24)
 8.57 
(9.62)
 61.38 
SHPH  4.18 (1.25) 0.00 (3.95) 0.00 
 0.00 
 8.40 
(9.02)
 50.96 
LFCR  3.16  0.78  0.15 (1.22) 3.66 
(3.39)
 8.08 
(5.61)
 20.91 
All Fundamental Data

Acorda Therapeutics Competitive Analysis

The better you understand Acorda Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Acorda Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Acorda Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ACOR TAIPY SGIOF OASMY PCRX SBFMW LSDI BFRI JUPW SHPH
 2.41 
 16.20 
Acorda
 0.00 
 14.00 
Taisho
 0.50 
 14.17 
Shionogi
 0.00 
 0.06 
Oasmia
 0.05 
 19.87 
Pacira
 37.50 
 0.22 
Sunshine
 0.00 
 0.02 
Lucy
 1.89 
 1.04 
Biofrontera
 1.69 
 0.58 
Jupiter
 2.86 
 0.68 
Shuttle
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very risky
Very steady
Very steady
Out of control
Very steady
Risky
Very steady
Out of control
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Insignificant
Very Weak
Good
Good
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Low
Dangerous
Below Average
Quite High
Dangerous
Very High
Dangerous
Very High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Not Rated
Cautious Hold
Strong Sell
Not Rated
Strong Sell
Not Rated
Strong Sell
Current Ratio
1.71
6.21
5.27
6.8
3.95
85.09
N/A
3.16
2.84
0.03
Net Asset
117.75 M
888.16 B
1.15 T
594.31 M
1.57 B
27.35 M
8.78 M
27.93 M
8.69 M
5.95 M
Profit Margin
-2.15
0.0847
0.44
N/A
-0.13
-0.13
N/A
-0.38
-2.1
N/A
EBITDA
8.4 M
42.81 B
143.46 B
(97.54 M)
157.58 M
(3.82 M)
(5.66 M)
(18.45 M)
(10.97 M)
(5.89 M)
Operating Margin
0.039
0.0904
0.43
N/A
0.13
-0.13
-89.07
-0.65
-1.92
N/A
Current Valuation
161.45 M
1.27 B
11.39 B
6.58 M
1.11 B
N/A
2.04 M
6.33 M
23.17 M
2.92 M
Price To Book
0.0527
0.57
2.01
0.68
1.22
N/A
0.43
1.49
2.54
4.16
Retained Earnings
(1.19 B)
N/A
524.07 B
N/A
(106.8 M)
(63.91 M)
(44.42 M)
(99.65 M)
(50.6 M)
(15.49 M)
Current Asset
451.32 M
N/A
324.6 B
N/A
252.58 M
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
1.57
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.46
0.26
0.57
0.0522
0.82
-1.04
N/A
0.51
0.5
0.74
Number Of Employees
102
9.13 K
5.69 K
17
711
44
2
83
10
8
Shares Outstanding
1.24 M
327.94 M
298.16 M
179.35 M
46.17 M
N/A
1.76 M
7.75 M
27.45 M
3.66 M
Cash Flow From Operations
(13.98 M)
28.51 B
102.07 B
(145.56 M)
154.65 M
(8.78 M)
(4.27 M)
(24.89 M)
(6.4 M)
(5.58 M)
Annual Yield
N/A
0.0179
0.0194
0.12
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
190.9 M
N/A
6.65 B
N/A
586.04 M
657.71 K
1.79 M
5.4 M
2.73 M
1.09 M
Return On Equity
-0.24
0.0345
0.2
-0.25
-0.11
-0.18
N/A
-1.49
-1.53
-1.86
Z Score
N/A
N/A
1.2
N/A
N/A
N/A
N/A
N/A
-4.24
N/A
Return On Asset
-0.0577
0.0183
0.11
-0.0875
0.0417
-0.11
-0.99
-0.4
-0.56
-0.62
Number Of Shares Shorted
8.1 K
N/A
N/A
20.72 K
4.8 M
5.01 K
2.68 K
686.56 K
2.45 M
56.85 K
Book Value Per Share
-127.17
2413.12
3585.51
N/A
16.24
12.52
0.046
3.16
0.21
2.02
Current Liabilities
90.59 M
N/A
59.48 B
N/A
149.79 M
N/A
N/A
N/A
N/A
N/A
Total Asset
117.75 M
888.16 B
1.15 T
594.31 M
1.57 B
27.35 M
8.78 M
27.93 M
8.69 M
5.95 M
Debt To Equity
2.56
N/A
0.006
0.011
1.1
8.98
N/A
N/A
0.31
0.091
Short Ratio
1.84
N/A
N/A
0.03
8.62
N/A
N/A
0.08
1.83
0.25
Target Price
10.0
N/A
16.97
6.0
18.13
N/A
35.0
11.5
N/A
N/A
Last Dividend Paid
N/A
50.0
120.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
13.22
N/A
52.78
N/A
97.9
N/A
7.08
20.6
18.71
1.81
Market Capitalization
821.03 K
3.35 B
14.11 B
21.21 M
917 M
N/A
906.91 K
8.21 M
32.12 M
2.51 M
Price To Earning
0.95
20.67
15.47
N/A
14.34
N/A
N/A
N/A
N/A
N/A
Price To Earnings To Growth
0.51
N/A
14289.2
N/A
-3.83
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.007
0.0119
0.0442
31.16
1.32
N/A
54.2
0.23
3.04
N/A
Net Income
(252.85 M)
13.12 B
114.19 B
(132.72 M)
41.95 M
(4.51 M)
(8.99 M)
(20.13 M)
(15.22 M)
(6.59 M)
Earnings Per Share
-203.57
0.49
2.98
N/A
-1.98
-2.21
-7.64
1.16
-0.51
-4.25
Shares Owned By Insiders
0.69
N/A
4.66
N/A
2.1
N/A
30.39
32.06
44.96
27.8
Revenue
117.63 M
268.2 B
335.14 B
26.19 M
674.98 M
24.09 M
7.05 K
34.07 M
6.2 M
N/A
Working Capital
(152.98 M)
N/A
265.13 B
N/A
412.61 M
19.34 M
1.11 M
4.99 M
2.25 M
4.55 M
Cash And Equivalents
20.7 M
276.54 B
502.8 B
N/A
316.39 M
40.56 M
N/A
31.91 M
3.57 M
50.44 K
Cash Per Share
0.85
843.28
N/A
N/A
6.9
1.8
N/A
1.36
0.16
N/A
Gross Profit
82.43 M
163.83 B
279.72 B
(15.25 M)
393.23 M
110.6 K
2.55 K
13.49 M
535.49 K
N/A
Day Typical Price
15.99
14.0
14.17
0.06
19.76
0.2
0.02
1.06
0.58
0.69
Accumulation Distribution
0.0861
N/A
N/A
N/A
39185.41
0.27
N/A
66244.19
0.082
8396.17
Market Facilitation Index
1.43
N/A
N/A
N/A
0.0
0.06
N/A
N/A
0.05
0.0
Daily Balance Of Power
(0.28)
0.0
9.2 T
0.0
0.0089
1.0
0.0
(0.14)
(0.20)
(0.33)
Period Momentum Indicator
(0.40)
N/A
0.07
N/A
0.01
0.06
N/A
(0.02)
(0.01)
(0.02)
Rate Of Daily Change
0.98
1.0
1.0
1.0
1.0
1.38
1.0
0.98
0.98
0.97
Day Median Price
15.89
14.0
14.17
0.06
19.7
0.19
0.02
1.07
0.59
0.69
Price Action Indicator
0.11
N/A
0.035
N/A
0.17
0.06
N/A
(0.04)
(0.01)
(0.02)
Coefficient Of Variation
1032.27
17723.13
911.5
35042.85
532.67
642.28
N/A
64507.34
1826.69
(551.72)
Mean Deviation
5.6
0.6597
12.35
5.71
2.05
17.95
N/A
6.4
4.58
4.18
Jensen Alpha
1.19
0.0081
4.06
(0.21)
0.5594
4.17
N/A
(0.05)
0.4155
(1.25)
Total Risk Alpha
(0.1)
(0.26)
0.1905
(2.43)
0.2303
1.25
N/A
(0.91)
(0.40)
(1.92)
Sortino Ratio
0.1739
(0.02)
0.101
N/A
0.2037
0.1929
N/A
(0.01)
0.056
N/A
Downside Variance
35.25
20.52
1568.19
N/A
5.0
375.59
N/A
65.15
38.31
N/A
Standard Deviation
11.54
2.56
37.23
23.84
2.88
24.56
N/A
8.79
7.89
6.69
Kurtosis
30.45
29.4
24.26
27.06
7.55
1.54
N/A
1.68
21.02
13.18
Potential Upside
14.01
N/A
6.53
N/A
4.58
52.17
N/A
14.63
8.57
8.4
Treynor Ratio
(1.01)
(0.09)
24.94
0.0161
(1.39)
(0.81)
N/A
0.0047
4.79
(3.95)
Maximum Drawdown
95.04
16.67
272.95
190.0
17.06
110.63
N/A
46.72
61.38
50.96
Variance
133.16
6.56
1386.19
568.28
8.3
603.36
N/A
77.35
62.33
44.82
Market Risk Adjusted Performance
(1.00)
(0.08)
24.95
0.0261
(1.38)
(0.80)
N/A
0.0147
4.8
(3.94)
Risk Adjusted Performance
0.0793
0.0113
0.089
0.0118
0.1431
0.1221
N/A
0.0103
0.0486
(0.12)
Skewness
4.75
3.71
4.53
3.63
1.6
1.06
N/A
0.7932
3.47
2.56
Semi Deviation
5.26
1.4
12.25
N/A
1.82
15.52
N/A
7.29
4.91
N/A
Information Ratio
0.0895
(0.03)
0.1074
(0.0007)
0.1581
0.1522
N/A
(0.01)
0.0439
(0.19)
Value At Risk
(9.57)
(0.78)
(7.59)
(16.67)
(3.21)
(28.00)
N/A
(11.70)
(9.62)
(9.02)
Expected Short fall
(6.81)
(7.27)
(84.96)
N/A
(2.46)
(24.81)
N/A
(8.02)
(6.24)
N/A
Downside Deviation
5.94
4.53
39.6
N/A
2.24
19.38
N/A
8.07
6.19
N/A
Semi Variance
27.67
1.97
150.11
N/A
3.31
240.78
N/A
53.14
24.11
N/A

Acorda Therapeutics Competition Performance Charts

Five steps to successful analysis of Acorda Therapeutics Competition

Acorda Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Acorda Therapeutics in relation to its competition. Acorda Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Acorda Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Acorda Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Acorda Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Acorda Therapeutics position

In addition to having Acorda Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SPAC Thematic Idea Now

SPAC
SPAC Theme
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Acorda Stock

If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY